NBIX Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$108.38 |
| 52 Week High | US$129.29 |
| 52 Week Low | US$73.13 |
| Beta | 0.52 |
| 1 Month Change | -8.68% |
| 3 Month Change | -6.22% |
| 1 Year Change | 41.25% |
| 3 Year Change | 8.29% |
| 5 Year Change | 30.06% |
| Change since IPO | 767.04% |
Recent News & Updates
Recent updates
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly
Jul 26Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?
Apr 11Here's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Might Deserve Your Attention Today
Jan 04We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Stay On Top Of Its Debt
Dec 09I Ran A Stock Scan For Earnings Growth And Neurocrine Biosciences (NASDAQ:NBIX) Passed With Ease
Oct 02Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Aug 27Earnings Not Telling The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Jun 08We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO For Now
May 13Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
May 04Introducing Neurocrine Biosciences (NASDAQ:NBIX), The Stock That Zoomed 210% In The Last Five Years
Mar 01We Think Neurocrine Biosciences' (NASDAQ:NBIX) Statutory Profit Might Understate Its Earnings Potential
Feb 02
Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?
Jan 12Shareholder Returns
| NBIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | 0.7% | 2.3% |
| 1Y | 41.2% | 7.1% | -9.7% |
Return vs Industry: NBIX exceeded the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: NBIX exceeded the US Market which returned -9.7% over the past year.
Price Volatility
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NBIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NBIX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,150 | Kevin Gorman | https://www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NBIX fundamental statistics | |
|---|---|
| Market Cap | US$10.42b |
| Earnings (TTM) | US$58.20m |
| Revenue (TTM) | US$1.39b |
179.0x
P/E Ratio7.5x
P/S RatioIs NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIX income statement (TTM) | |
|---|---|
| Revenue | US$1.39b |
| Cost of Revenue | US$452.80m |
| Gross Profit | US$935.90m |
| Other Expenses | US$877.70m |
| Earnings | US$58.20m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 06, 2023
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 67.39% |
| Net Profit Margin | 4.19% |
| Debt/Equity Ratio | 11.0% |
How did NBIX perform over the long term?
See historical performance and comparison